ArticleAntimicrobial agents and chemotherapy2016
Changing Epidemiology of Group B Streptococcus Susceptibility to Fluoroquinolones and Aminoglycosides in France.
Article in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Global patterns of antibiotic resistance in group BFrontiers in microbiology · 2025Pooled it
- Anti-Streptococcal Activity of β-Thujaplicin and Its Effect on Natural Low-Level Resistance ofPathogens (Basel, Switzerland) · 2026Article
- Prevalence, Serotype Distribution, and Antimicrobial Resistance ofJournal of clinical medicine · 2026Article
- Genetic Determinants and Clonal Composition of Levofloxacin-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Characterization of Penicillin-Non-Susceptible, Multidrug-Resistant Streptococcus agalactiae Using Whole-Genome Sequencing.Current microbiology · 2025Article
- Group B streptococcal infections in pregnancy and early life.Clinical microbiology reviews · 2025Review
- Prevalence and Antibiotic Resistance ofLife (Basel, Switzerland) · 2024Article
- A Review of the Impact of Streptococcal Infections and Antimicrobial Resistance on Human Health.Antibiotics (Basel, Switzerland) · 2024Review
- Microbiological Epidemiology of Invasive Infections Due to Non-Beta-Hemolytic Streptococci, France, 2021.Microbiology spectrum · 2023Article
- Evolving antibiotic resistance in Group B Streptococci causing invasive infant disease: 1970-2021.Pediatric research · 2023Article
- Antibiotic resistance genes and molecular typing of Streptococcus agalactiae isolated from pregnant women.BMC pregnancy and childbirth · 2023Article
- Epidemiology of Antimicrobial Resistance Genes inAntibiotics (Basel, Switzerland) · 2022Article
- Molecular characterization and antimicrobial resistance ofIJID regions · 2022Article
- Colonization of Group BPathogens (Basel, Switzerland) · 2022Article
- The landscape of antimicrobial resistance in the neonatal and multi-host pathogen group BFrontiers in microbiology · 2022Article
- Antimicrobial resistance in colonizing group B Streptococcus among pregnant women from a hospital in Vietnam.Scientific reports · 2021Article
- Whole genome sequence based capsular typing and antimicrobial resistance prediction of Group B streptococcal isolates from colonized pregnant women in Nigeria.BMC genomics · 2021Article
- Streptococcus agalactiae strains isolated from cancer patients in Rio de Janeiro, Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021Article
- Bacterial and Host Determinants of Group B Streptococcal Vaginal Colonization and Ascending Infection in Pregnancy.Frontiers in cellular and infection microbiology · 2021Review
- Emergence of Invasive Serotype Ib Sequence Type 10 Group B Streptococcus Disease in Chinese Infants Is Driven by a Tetracycline-Sensitive Clone.Frontiers in cellular and infection microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Group B Streptococcus (GBS) is the leading cause of neonatal invasive infections and an emerging pathogen in the elderly. Our objectives were to describe the evolution of GBS resistance to antibiotics in France and to investigate the emergence of fluoroquinolone (FQ)-resistant isolates. A total of 8,757 unrelated GBS isolates were collected and tested for antibiotic susceptibility from 2007 to 2014 according to EUCAST recommendations. All isolates were susceptible to penicillin G, amoxicillin, and vancomycin. Resistance to macrolides decreased from 47.0% to 30.0%, whereas high-level resistance to aminoglycosides, especially amikacin, increased from 6.4% to 8.8% and 24 isolates (0.3%) were highly resistant to gentamicin. FQ resistance gradually increased from 0.2% in 2007 (n = 1) to 1.5% in 2014 (n = 18, P < 0.01). Capsular polysaccharide (CPS) genotyping, multilocus sequence typing, and sequencing of the quinolone resistance-determining region (QRDR) showed that GBS isolates of sequence type 19 (ST-19) CPS type V were largely overrepresented in FQ-resistant isolates (n = 30, 45.5%). All 30 strains displayed the same QRDR mutations and were often associated with cross-resistance to macrolides (93.3%) and gentamicin (30%). In conclusion, we report the rise of FQ- and aminoglycoside-resistant GBS in France over an 8-year study period, an evolution likely linked to the clonal expansion of ST-19 CPS V-resistant isolates. This study emphasizes the need for a continuous surveillance of GBS epidemiology and antibiotic susceptibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.